ArticleCureus2025
Platelet Count of Zero: A Case of Vancomycin-Induced Immune Thrombocytopenia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an acquired hematologic disorder marked by immune-mediated destruction of platelets, leading to profound thrombocytopenia and increased bleeding risk. Drug-induced immune thrombocytopenia (DITP), specifically vancomycin-induced immune thrombocytopenia (VIIT), is a rare but serious adverse drug reaction, caused by drug-dependent antibodies that accelerate platelet clearance. We present a case of a 72-year-old male who developed life-threatening thrombocytopenia, with a nadir of <1 K/µL, following re-exposure to vancomycin. The decline began within three days of treatment reinitiation and persisted despite platelet transfusions, corticosteroids, and intravenous immunoglobulin (IVIG). A diagnosis of VIIT was made after excluding other etiologies, including heparin-induced thrombocytopenia (HIT), thrombotic microangiopathy, and sepsis-associated thrombocytopenia. Platelet counts remained refractory until plasmapheresis and drug discontinuation, with recovery to 71 K/µL within one week. This case highlights the importance of early recognition of VIIT and suggests a potential role for plasmapheresis in refractory cases. Prompt drug discontinuation is critical for recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.